Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
Astellas Pharma already has the first FDA approval for a therapy that goes after Claudin 18.2, a protein whose overexpression ...
Astellas Pharma already has the first FDA approval for a therapy that goes after Claudin 18.2, a protein whose overexpression ...
Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part ...
An Astellas Pharma drug designed to address a novel target has landed a highly anticipated FDA approval for a rare ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.